ライフサイエンスコーパス: vaginal bleeding

1 differential diagnosis of sudden and massive vaginal bleeding.

2 dergoing pelvic scans for reasons other than vaginal bleeding.

3 ogic evaluation in postmenopausal women with vaginal bleeding.

4 ynecologic follow-up for persistent abnormal vaginal bleeding.

5 r uterine segment with a history of painless vaginal bleeding.

6 transient hemorrhagic cystitis (1 patient), vaginal bleeding (2 patients), gastrointestinal bleeding

7 women in the hormone group who did not have vaginal bleeding (3.8+/-4.3 vs. 0.7+/-1.5 nodes, P=0.006

8 v 14/203 (6.9%); -5.0%, -8.9% to -1.0%), and vaginal bleeding (3/208 (1.4%) v 13/203 (6.4%); -5.0%, -

9 Vaginal bleeding (54.1% v 5.2% at 6 months) and breast c

10 rasound images obtained in 516 patients with vaginal bleeding, a live fetus, and a subchorionic hemat

11 ominal pain, nausea, vomiting, diarrhea, and vaginal bleeding also increased with advancing gestation

12 After adjusting for postrandomization vaginal bleeding and breast changes, bowel examinations

13 DHT altered the duration of vaginal bleeding and delayed restoration of the luminal

14 The overall association between vaginal bleeding and preterm birth was modest (risk rati

15 a 46-year-old lady who presented with heavy vaginal bleeding and ultrasound/colour Doppler evidence

16 teoporosis/osteopenia, hypertriglyceridemia, vaginal bleeding, and hypercholesterolemia were less fre

17 amnionitis, maternal antibiotics, antepartum vaginal bleeding, and labor lasting less than 4 hours.

18 Fibroids (1167 [78.1%]), vaginal bleeding, and pelvic pain (857 [57.4%]) were the

19 likely to produce weight gain, dyspnea, and vaginal bleeding, and the letrozole groups were more lik

20 iple logistic regression which also included vaginal bleeding as a predictor.

21 Smoking and vaginal bleeding before 15 weeks were the only significa

22 Exclusion criteria included vaginal bleeding, blood transfusion or major surgery wit

23 w-dose aspirin was associated with increased vaginal bleeding, but this adverse event was not associa

24 Patients may present with vaginal bleeding caused by endometrial hyperplasia or ut

25 Vaginal bleeding events were defined as any vaginal bleeding complications as reported by the patien

26 o investigate the management and outcomes of vaginal bleeding complications during therapy with direc

27 vide guidance on prevention and treatment of vaginal bleeding complications in this patient populatio

28 ively, but patients with severe or recurrent vaginal bleeding complications should be assessed for un

29 The presence of abdominal pain or vaginal bleeding during early pregnancy should prompt a

30 estigated the relation between self-reported vaginal bleeding during pregnancy and preterm birth in a

31 Vaginal bleeding events were defined as any vaginal blee

32 factor Xa inhibitor therapy, of whom 57 had vaginal bleeding events, including 50 who received rivar

33 These 57 women had 72 vaginal bleeding events, including 59 cases of heavy men

34 and mortality; and pattern and management of vaginal bleeding events.

35 The most common adverse event was vaginal bleeding for all of the 3 management groups (44.

36 rovided daily urine specimens and records of vaginal bleeding for up to 1 year or until clinical preg

37 rning urine specimens and recorded days with vaginal bleeding for up to 6 months.

38 n of endometrial biopsies required to assess vaginal bleeding further limits the acceptability of thi

39 , women in the hormone group with antecedent vaginal bleeding had colorectal cancers with a greater n

40 sulted in abdominal pain in 73% of women and vaginal bleeding in 32% compared with 3% and 0%, respect

41 one, as compared with placebo, in women with vaginal bleeding in early pregnancy.

42 ks (31.2%) and those with a short cervix and vaginal bleeding in the first half of pregnancy (40%).

43 Associations with antepartum vaginal bleeding (increased risk) and preeclampsia (decr

44 Postmenopausal vaginal bleeding is a common clinical problem.

45 There were no significant differences in vaginal bleeding, mood alteration, or low energy.

46 nemia (n = 2), other cardiovascular (n = 2), vaginal bleeding (n = 1), neutropenia (n = 1), and fistu

47 Raloxifene did not cause vaginal bleeding or breast pain and was associated with

48 ents with uterine LMS typically present with vaginal bleeding, pain, and a pelvic mass.

49 Vaginal bleeding, particularly heavy menstrual bleeding,

50 Knowing the expected vaginal bleeding pattern for each hormone replacement th

51 peri- and postmenopausal women with abnormal vaginal bleeding seen in clinical practice.

52 r maternal age, smoking, and first-trimester vaginal bleeding, standard guidelines for adjudicating d

53 r more pregnant women with abdominal pain or vaginal bleeding that evaluated patient history, physica

54 One woman had minimal vaginal bleeding; there were no adverse events.

55 Baseline symptom prevalence ranged from 2% (vaginal bleeding) to 60% to 70% (bone/muscle aches and l

56 om timed matings of FG(-/-) mice showed that vaginal bleeding was initiated as early as embryonic day

57 Vaginal bleeding was not associated with preterm birth a

58 Breast tenderness and atypical vaginal bleeding were the most frequently reported adver

59 use endometrial epithelium is sufficient for vaginal bleeding when combined with PI3K activation.

60 ; to features of congestive heart failure to vaginal bleeding which may at times life be threatening.

61 se event (severe anaemia secondary to excess vaginal bleeding), which was deemed to be possibly relat

62 reliably identify postmenopausal women with vaginal bleeding who are highly unlikely to have signifi

63 For a postmenopausal woman with vaginal bleeding with a 10% pretest probability of endom

64 he/visual disturbances; chest pain/dyspnoea; vaginal bleeding with abdominal pain; systolic blood pre

65 tid endarterectomy presented with 3 weeks of vaginal bleeding with passage of clots.

66 DUB is defined as abnormal vaginal bleeding without an identifiable pathologic cond